Table 4.

Efficiency and safety of photon or particle radiotherapy for limited-stage small cell lung cancer.

Resource	Number	Radiotherapy	Follow-up (months)	Dose	Median OS	Median PFS	Survival rate				Toxicity (grade ≥3 non-hematological)
								1 year	2 years	5 years
Komaki et al., 2012 a (39)	71	Photon	19.0	61.2 Gy/34 fractions	19	9.9	OS	−	36.6	−	Acute
							PFS	−	19.7	−	Esophageal toxicity 18.3
											Pulmonary toxicity 12.7
											Late
											Esophageal toxicity 1.4
											Pulmonary toxicity 11.3
Bogart et al., 2004 b (17)	63	Photon	24.7	70 Gy/35 fractions	22.4	13.4	OS	−	48	−	Esophageal toxicity 21
							PFS	−	31	−	Pulmonary toxicity 5
Takada et al., 2002 c (12)	231	Photon	−	45 Gy/30 fractions	19.7/27.2	−	OS	−	35.1/54.4	18.3/23.7	Esophagitis 4/9
Murray et al., 1993 d (40)	308	Photon	60	40 Gy/15 fractions	21.2/16	15.4/11.8	OS	−	40/33.7	20/11	Esophagitis 14.8/7.6
							PFS	−	−	(3 years) 26/19
Sun et al., 2013 e (41)	219	Photon	59.4	52.5 Gy/25 fractions	24.1/26.8	12.4/11.2	OS	−	50.7/56.0	24.3/24.0	Esophagitis 3.6/0.9
							PFS	51.8/48.1	28.0/23.5	−	Pneumonitis 4.5/2.8
Jeremic et al., 1997 f (35)	103	Photon	−	54 Gy/36 fractions	34/26	–	OS LPFS	90/71 94/74	71/53 90/69	30/15 58/37	Acute Esophageal toxicity 28.8/25.5 Pulmonary toxicity 1.9/0 Late Esophageal toxicity 1.9/2.0 Pulmonary toxicity 1.9/0
Work et al., 1997 g (42)	199	Photon	–	40 - 45 Gy/22 fractions	10.5/12.0	–	OS LC h	- -	20/19 28/32	11/12 23/27	–
Turrisi et al., 1999 i (36)	417	Photon	96	45 Gy/30 fractions	23/19	−	OS	−	47/41	26/16	Esophagitis 32/16
				45 Gy/25 fractions			PFS	−	29/24	−	Pulmonary toxicity 6/4
Faivre-Finn et al., 2017 i (14)	547	Photon	45	45 Gy/30 fractions	30.0/25.0	15.4/14.3	OS	−	56.0/51.0	34.0/31.0	Acute
				66 Gy/33 fractions			LPFS j	−	45.8/41.5	−	Esophagitis 19/19 Pneumonitis 3/2 Late Esophagitis 0/2 Pneumonitis 2/3
Grønberg et al., 2021 k (18)	170	Photon	49	60 Gy/40 fractions	37.2/22.6	18.6/10.9	OS	−	74.2/48.1	−	Esophagitis 21/18
				45 Gy/30 fractions			PFS j	−	42.7/32.1	−	Pneumonitis 3/0
Colaco et al., 2013 (21)	6	Proton	12.0	45 CGE/30 fractions	−	−	OS	83			Esophagitis 0
				60–66 CGE/30–34 fractions			PFS	66			Pneumonitis 0
Rwigema et al., 2017 (20)	30	Proton	14.0	45 CGE/30 fractions	28.2	14.3	OS	71.5	57.6		Esophagitis 3.3
				59.4–66.6 CGE/33–37 fractions			PFS	63.0	42.0		Pneumonitis 3.3
							LC	85.0	68.6

^aPhoton, 61.2 Gy (daily, 1.8-Gy fractions on days 1–22, then twice daily, 1.8-Gy fractions on days 23–33).

^bPhoton, 70 Gy (daily, 2-Gy fractions).

^cPhoton, sequential or concurrent radiotherapy.

^dPhoton, early (weeks 3–6 after the start of chemotherapy) vs. late radiotherapy (weeks 15–18).

^ePhoton, early (during first chemotherapy) radiotherapy or late (during third chemotherapy) radiotherapy.

^fPhoton, early (weeks 1–4 concurrent with chemotherapy) vs. late radiotherapy (weeks 6–9).

^gPhoton, early (before sequential chemotherapy) vs. late (weeks 18 after the start of sequential chemotherapy) radiotherapy.

^hLC, % without in-field chest recurrence.

ⁱPhoton, twice daily or once daily.

^jEstimated.

^kPhoton, high dose (twice daily) vs. standard dose (twice daily).

CGE, cobalt gray equivalent; LPFS, local progression-free survival; OS, overall survival; LC, local control; PFS, progression-free survival.